2026-04-26T23:29:40Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89622024-09-27T22:14:07Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Perez-Olmeda, Mayte author Sánchez-Seco, María Paz author Vazquez, Ana author Balfagon, Pilar author Fuente, Jesus de la author Murillo, Maria Angeles author Minguito, Teodora author De Ory, Fernando de author 2020-01-07 The aim of this study is to evaluate the performance characteristics of the LIAISON XL Zika Capture IgM II. For this purpose we tested 128 samples obtained from recent infections caused by the Zika (ZIKV; 74 samples), dengue (DENV; 10 samples), chikungunya (CHIK V; 11 samples), rubella (RUBV; 10 samples) and measles (MeV; 10 samples) viruses, as well as human parvovirus B19 (HPVB19; 13 samples). The results of the assay under evaluation are compared with those obtained from an indirect immunofluorescence (IIF) assay, and the discrepancies are resolved by considering other laboratory results (PCR and a plaque-reduction neutralization test). The LIAISON showed excellent sensitivity (100%). The specificity (91.25%) was hampered by some false-positive results in recent dengue virus, chikungunya virus, measles virus and human parvovirus B19 infections. The method evaluated is adequate, but the low specificity makes it necessary to consider the clinical and epidemiological contexts of patients, as well as other laboratory results. Viruses. 2020 Jan 7;12(1). pii: E69. 1999-4915 http://hdl.handle.net/20.500.12105/8962 31936013 10.3390/v12010069 1999-4915 Viruses Zika virus Chemiluminescent immunoassay Chikungunya virus Dengue viruses Enzyme immunoassay Evaluation of the LIAISON XL Zika Capture IgM II for the Diagnosis of Zika Virus Infections